Bacterial DNA (Helicobacter pylori) (H. pylori DNA)

Helicobacter pylori is a Gram-negative, microaerophilic bacterium that colonizes the human gastric mucosa and is a primary causative agent of chronic gastritis, peptic ulcers, and gastric adenocarcinoma (WHO, 2020). Its DNA serves as the essential genetic blueprint for the organism's survival in the acidic stomach environment, encoding critical virulence factors such as urease and the CagA protein. As a therapeutic target, H. pylori DNA is the site of action for several classes of antibiotics used in eradication protocols. Nitroimidazoles, such as metronidazole, function as prodrugs that are reduced within the bacterium to create reactive oxygen species that cause catastrophic DNA strand breaks (PubMed, 2021). Additionally, the structural integrity and replication of the DNA are compromised by fluoroquinolones, which inhibit the enzymes DNA gyrase and topoisomerase IV (Nature Reviews Microbiology, 2023). Successful targeting of the bacterial DNA is necessary to achieve complete eradication of the infection and reduce the long-term risk of gastric malignancy. However, the increasing prevalence of genetic mutations leading to antibiotic resistance remains a significant challenge in clinical management.

Other names

Helicobacter pylori genomeH. pylori deoxyribonucleic acidBacterial chromosome (Helicobacter pylori)

Nitroimidazoles like metronidazole are reduced by bacterial electron transport proteins to form reactive metabolites that cause direct oxidative damage and lethal strand breakage of the bacterial DNA (StatPearls, 2023). Fluoroquinolones, such as levofloxacin, target the DNA-enzyme complex by inhibiting DNA gyrase and topoisomerase IV, which prevents the relaxation of supercoiled DNA and halts replication and transcription (NCBI, 2022). Rifamycins like rifabutin inhibit the DNA-dependent RNA polymerase, preventing the transcription of DNA into mRNA (PubMed, 2021).